Conn. gets $1.7 M in diabetes drug settlement
HARTFORD, Conn. (AP) — Connecticut is getting nearly $1.7 million to settle claims that British drug maker GlaxoSmithKline LLC deceptively promoted the diabetes drug Avandia.
The payment is part of a $90 million settlement between GlaxoSmithKline and attorneys general from 38 different states.
Connecticut officials say $100,000 from the state's share of the settlement will support the Department of Consumer Protection. Another $100,000 will go to the Office of the Attorney General's General Consumer Fund.
Attorney generals say GlaxoSmithKline misrepresented Avandia's cardiovascular risks and safety profile. The agreement requires the company to reform its marketing practices and to publicize information about any company-sponsored clinical trials on its diabetes drugs.
GlaxoSmithKline doesn't admit any wrongdoing. A spokeswoman says the company firmly believes it acted responsibly in testing, marketing and monitoring the safety of Avandia.
The settlement was announced on Thursday.
News Photo Galleriesview all
- 11867Oklahoma tornadoes: Plaza Towers Elementary School teacher shoved students into bathroom as wall collapsed
- 11199Oklahoma tornadoes: Cost, custom keep basements scarce
- 7813Finding Addyson – One family's struggle in the Moore tornado
- 7743Oklahoma tornadoes: The 'Big Dog,' the little boy and the hug that triumphs over tragedy
- 4737Downtown wish list includes Super Target
- 4255OU softball: Sooners inspired by Casey Angle, run-rule Texas A&M
- 3606Miranda Lambert, Reba McEntire, Vince Gill to join Blake Shelton at "Healing in the Heartland" Oklahoma tornado benefit